 Charlottesville, VA -- Biotechnology company Hemoshear has secured $8.7 million in Series C financing, according to a company statement.
Hemoshear has developed technology that provides cell-based human surrogate models of organ systems.
Investors in the round were not disclosed.
Hemoshear said that it will relocate its operations and accelerate development of its human disease modeling systems. |